recombinant sars-cov-2 vaccine
VaccineexperimentalCOVID-19
Clinical trial activity
33 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
18
Phase 3
7
Phase 4
2
Earliest trial started Jun 22, 2020 (NCT04445194)
Timeline
Indications
Approved for
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06043388 | Phase 1 | Sep 30, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT06025812 | N/A | Sep 20, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05770180 | Phase 2 | Mar 30, 2023 | Government of China |
| NCT05850507 | N/A | Mar 17, 2023 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05765604 | Phase 1 | Mar 14, 2023 | Government of China |
| NCT05616754 | Phase 3 | Nov 7, 2022 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05552573 | Phase 1 | Jul 19, 2022 | Government of China |
| NCT05716347 | Early Phase 1 (Phase 1) | Jul 13, 2022 | Binhui Biopharmaceutical Co., Ltd. |
| NCT05895110 | N/A | Apr 29, 2022 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
| NCT05890521 | Phase 4 | Apr 2, 2022 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05273541 | Phase 1/Phase 2 (Phase 2) | Feb 11, 2022 | People's Liberation Army of China |
| NCT05246137 | Phase 3 | Feb 3, 2022 | Laboratorios Hipra, S.A. |
| NCT05198063 | Phase 1/Phase 2 (Phase 2) | Jan 10, 2022 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05198102 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05205083 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05109598 | Phase 2 | Nov 4, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05205096 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05128643 | Phase 3 | Sep 17, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
| NCT05033847 | Phase 3 | Sep 12, 2021 | China National Biotec Group Co., Ltd, National Vaccine and Serum Institute, China |
| NCT05091411 | Phase 3 | Sep 9, 2021 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Government of China |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | For profit | 20 | 20 | 5 | 2020 |
| Government of China | Government | 16 | 5 | 5 | 2020 |
| People's Liberation Army of China | Government | 5 | 3 | 4 | 2020 |
| China National Biotec Group Co., Ltd | For profit | 2 | 0 | 2 | 2021 |
| National Vaccine and Serum Institute, China | For profit | 2 | 2 | 2 | 2021 |
| Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Binhui Biopharmaceutical Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2020 |
| Laboratorios Hipra, S.A. | For profit | 1 | 1 | 1 | 2022 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2020 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2021 |
13 organizations
Page 1 / 1